B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $72 to $120
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $60 to $120
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Analyst Ratings
Cytokinetics Hold Rating: Balancing Promising Commercial Strategy With Execution Risks and Market Uncertainties
Barclays Remains a Buy on Cytokinetics (CYTK)
Cytokinetics: Strategic Growth and Promising Cardiology Pipeline Justify Buy Rating
Cytokinetics Analyst Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $120
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $90
Buy Rating Affirmed for Cytokinetics Following Promising Aficamten Clinical Trial Results
Cytokinetics Analyst Ratings
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $60 to $92
Truist Financial Issues a Buy Rating on Cytokinetics (CYTK)
Cytokinetics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Buy Rating Affirmed for Cytokinetics: Aficamten's Promising Future in HCM Treatment
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92